Explore the details of the Novo Nordisk Inc. V. Meitheal Pharmaceuticals, Inc. case under case number 1:23-cv-01195 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:23-cv-01195
Filing Date
Oct 20, 2023
Cause of Action
Patent Infringement
Status
-
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Novo Nordisk Inc. -
Meitheal Pharmaceuticals, Inc. -
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. -

Patents Involved in the Case

This case involves 2 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US9265893B2
-US8114833B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Oct 20, 2023COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Meitheal Pharmaceuticals, Inc., Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. ( Filing fee $ 402, receipt number ADEDC-4254543.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet) (vfm) (Entered: 10/23/2023)PACER Document
Oct 20, 2023Summons Issued as to Meitheal Pharmaceuticals, Inc. on 10/20/2023; Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. on 10/20/2023. (Attachments: # 1 Summons Issued) (vfm) (Entered: 10/23/2023)PACER Document
Oct 20, 2023Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo Nordisk A/S, Corporate Parent Novo Nordisk US Holdings Inc., Corporate Parent Novo Nordisk Commercial Holdings, Inc. for Novo Nordisk Inc.; Corporate Parent Novo Nordisk Foundation for Novo Nordisk A/S filed by Novo Nordisk A/S, Novo Nordisk Inc.. (vfm) (Entered: 10/23/2023)PACER Document
Oct 20, 2023Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,114,833 B2 ;9,265,893 B2. (vfm) (Entered: 10/23/2023)PACER Document
Oct 20, 2023Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/08/2023. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 3/8/2026. (vfm) (Entered: 10/23/2023)PACER Document
Oct 20, 2023Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 10/23/2023)PACER Document
Oct 20, 2023COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Meitheal Pharmaceuticals, Inc., Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. ( Filing fee $ 402, receipt number ADEDC-4254543.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet) (vfm) (Entered: 10/23/2023)Attachment
Oct 20, 2023COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Meitheal Pharmaceuticals, Inc., Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. ( Filing fee $ 402, receipt number ADEDC-4254543.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet) (vfm) (Entered: 10/23/2023)Attachment